MLYS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
246.0M
+442.7%
45.3M
+18.4%
38.3M
-6.9%
41.1M
-12.0%
46.7M
R&D
221.4M
+808.6%
24.4M
-0.2%
24.4M
-22.4%
31.4M
-17.8%
38.3M
SG&A
24.7M
+17.6%
21.0M
+51.1%
13.9M
+43.4%
9.7M
+14.3%
8.5M
Operating Income
-246040000
-442.7%
-45340000
-18.4%
-38280000
+6.9%
-41131000
+12.0%
-46746000
EBITDA
-246035000
-442.7%
-45334000
-18.5%
-38267000
+6.9%
-41116000
+12.0%
-46730000
Net Income
-241071000
-512.8%
-39339000
-22.0%
-32234000
+12.7%
-36932000
+14.7%
-43274000
EPS (Basic)
$-2.85
-506.4%
$-0.47
-17.5%
$-0.40
+23.1%
$-0.52
+21.2%
$-0.66
EPS (Diluted)
$-2.85
-506.4%
$-0.47
-17.5%
$-0.40
+23.1%
$-0.52
+21.2%
$-0.66
Shares (Diluted)
84.7M
+2.3%
82.8M
+1.7%
81.4M
+15.3%
70.6M
+7.9%
65.5M
Mineralys Therapeutics (MLYS) โ€” Financials